The global clinical trials market size was estimated at USD 89.0 billion in 2025 and is projected to reach USD 158.4 billion by 2033, growing at a CAGR of 7.7% from 2026 to 2033. The market growth is primarily driven by the rising prevalence of chronic and rare diseases, continuous advancements in precision medicine and biotechnology, the expansion of decentralized and virtual clinical trials, and increasing research and development investments by pharmaceutical and biotechnology companies. The growing need for effective treatment solutions, combined with increasing demand for personalized therapies and advanced drug development processes, is significantly contributing to the expansion of the clinical trials market globally. In addition, supportive regulatory frameworks and increasing collaborations among healthcare organizations are further accelerating market growth during the forecast period.

The market growth is also attributed to the increasing trend of outsourcing clinical trial services to contract research organizations (CROs), which helps pharmaceutical and biotechnology companies reduce operational costs, improve efficiency, and accelerate drug development timelines. The rising prevalence of chronic conditions such as cancer, diabetes, cardiovascular diseases, and neurological disorders is creating a growing demand for innovative therapies and advanced treatment options, thereby increasing the number of clinical studies worldwide. Furthermore, the increasing complexity of drug development procedures and the growing emphasis on patient-centric trial approaches are encouraging the adoption of advanced clinical trial management systems and digital technologies. These factors are collectively supporting the steady growth of the clinical trials industry across developed and emerging markets.

In addition, the growing number of pharmaceutical and medical device companies, rapid advancements in digital health technologies, increasing adoption of personalized medicine, and expanding global partnerships are expected to drive the growth of the clinical trials industry over the forecast period. Technologies such as artificial intelligence, machine learning, big data analytics, wearable devices, and remote patient monitoring systems are improving patient recruitment, trial monitoring, data collection, and overall clinical trial efficiency. The increasing adoption of decentralized clinical trial models is also enhancing patient participation and reducing geographical barriers in clinical research. Moreover, rising investments in biologics, gene therapies, and precision medicine are further creating new growth opportunities for clinical trial service providers globally.

Download a free sample copy of the Clinical Trials market report to understand detailed coverage and inclusions in the final report

Key Market Trends & Insights

• North America clinical trials market held the largest global share of 50.7% in 2025. The regional market dominance is supported by the strong presence of leading pharmaceutical and biotechnology companies, advanced healthcare infrastructure, favorable regulatory environments, and high research and development spending across the United States and Canada. The region also benefits from a well-established network of research institutions, academic centers, and contract research organizations that actively support clinical trial activities. In addition, increasing government funding for healthcare research and the growing adoption of innovative clinical technologies are contributing significantly to the growth of the clinical trials market in North America.
• The U.S. clinical trials industry is expected to grow lucratively from 2026 to 2033. The country’s growth is driven by increasing investments in drug discovery and development, rising demand for precision medicine, and strong participation from pharmaceutical, biotechnology, and medical device companies. The presence of advanced regulatory systems, robust healthcare infrastructure, and a large patient population further supports the expansion of clinical trial activities across the country. Additionally, the growing focus on oncology research, rare disease treatments, and personalized healthcare solutions is accelerating the number of clinical studies being conducted in the U.S. market.
• By phase, the phase III segment held the largest market share of 53.6% in 2025. The dominance of this segment is primarily attributed to the large-scale testing requirements associated with phase III clinical trials, which involve evaluating the safety and effectiveness of new drugs and therapies in large patient populations before regulatory approval. These trials are generally more complex, time-consuming, and expensive compared to earlier trial phases, leading to higher market revenue generation. In addition, the increasing number of late-stage pipeline drugs and biologics is further driving demand for phase III clinical trial services globally.
• By study design, the interventional trials segment held the largest market share in 2025. The growth of this segment is driven by the increasing number of studies focused on testing new drugs, medical devices, biologics, vaccines, and therapeutic procedures. Interventional trials are essential for evaluating treatment outcomes, safety profiles, and clinical effectiveness under controlled conditions. Pharmaceutical and biotechnology companies are increasingly investing in interventional studies to accelerate regulatory approvals and bring innovative therapies to market efficiently. Moreover, advancements in digital monitoring technologies and data management systems are improving the efficiency and accuracy of interventional clinical studies.
• By indication, the oncology segment held the largest revenue share in 2025. The increasing global burden of cancer, rising investments in oncology drug development, and growing demand for targeted therapies and immunotherapies are major factors driving the growth of this segment. Pharmaceutical and biotechnology companies are significantly increasing research activities focused on cancer treatment innovations, including precision oncology, cell therapies, and personalized medicine approaches. In addition, increasing patient enrollment in oncology clinical trials and growing government support for cancer research programs are further contributing to the expansion of the oncology segment within the clinical trials market.

Looking for more specific insights? Customize this report to suite your business needs

Key Companies & Market Share Insights

The key players operating across the market are adopting strategic initiatives such as service launches, mergers & acquisitions, partnerships & agreements, and expansions to gain a competitive edge in the market. For instance, in February 2025, Summit Therapeutics Inc. announced a collaboration with Pfizer Inc. to conduct a clinical trial evaluating ivonescimab, an innovative investigational PD-1/VEGF bispecific antibody. This study will explore the use of ivonescimab in combination with various antibody drug conjugates (ADCs) developed by Pfizer, targeting multiple solid tumor indications.

Key Clinical Trials Companies:

• IQVIA Inc.
• Parexel International Corporation
• Thermo Fisher Scientific Inc.
• ICON Plc.
• LabCorp
• Syneos Health
• Novotech
• Avance Clinical
• George Clinical
• Veritus Research
• Eli Lilly and Company
• F. Hoffmann-La Roche Ltd.
• Novo Nordisk A/S
• Pfizer, Inc.
• Actinogen Medical
• Telix Pharmaceuticals
• PYC Therapeutics
• Neuren Pharmaceuticals
• AbbVie
• Merck Sharp & Dohme LLC

Explore Grand View Horizon to see global and regional level statistics related to the Clinical Trials Market

Grand View Research offers

• Focused market intelligence reports on specific geographies or high-growth segments.
• Extended forecast timelines for long-term planning.
• Competitor Benchmarking and Supply Chain Analysis
• Inclusion of regulatory and policy assessments.
• Inclusion of custom data models, KPIs, or applications unique to your business
• Specific high-impact Data Decks and Tables to support effective decision making
• And much more…

Looking for a report customized to your requirements? Explore our Custom Research Offering